Certainly, some may not have but some seem to think that 100k in short volume means there are 100k more shares short at the end of the day and then build their hopes that there will be some huge short squeeze.
Short volume is not the same as a short position. Day traders can short 1000 and buy it back several times a day and create thousands in short volume and end up with a position of zero. Short volume is meaningless. It increases when the PPS is making moves.
The uncertainty cloud about the future of the ALS treatment is whether or not they can identify the subgroup that will benefit from the cells. You don't want to be expediting disease progression for some. This is why the stock has lost half of its value. I agree that undoubtedly some patients lives have been extended greatly as a result of these cells.
That's the beauty of an anonymous message board. Everybody is an investment genius.
He's just a trading monkey that doesn't understand the medical aspects of this company. Who cares what he thinks
Just providing an alternative investment to STEM which faces delisting. Their next round of dilution will be even more painful
(CUR) has been initiated by analysts at MLV & Co. with a buy rating and a price target of $6 a share.
08:01 AM EDT, 04/28/2015 (MT Newswires) -- Coverage of biopharmaceutical company Neuralstem, Inc. (CUR) has been initiated by analysts at MLV & Co. with a buy rating and a price target of $6 a share.
The MRI data will be released when Dr. Fava (the lead investigator from Harvard) feels the data is complete and there is an appropriate forum to release the data to. They are not going to release it because some impatient retail investor wants a pop in the PPS.
This is standard before an offering like this. It happens in biotech all of the time. Those that have committed to buying the offer are given the opportunity to short at a price above the offering. This guarantees the offering will be fully subscribed. Call it crooked but that is the way it works.
A single patient does not constitute proof of efficacy. Jessi's progress can be shared with whomever they want
The scaffold may help the spinal cord heel in a position such that more connections can reestablish. The reestablishment of these connections may take time ... perhaps after the scaffold is gone. It's all speculation at this point and you certainly cannot say the improvement is not related to the scaffold. The animal studies certainly suggest that function after injury is better when the scaffold is used.
Starting in June. We could have results very quickly.... like 1 year or less.
Why do you keep on bumping this meaningless message. OCAT sells shares to Lincoln based the price from the previous 10 days or so. This is nothing new. Been doing this for at least a couple of years.
Why don't we just make up a bunch of conspiracies to explain this. That will make us feel better.